Claims
- 1. Compounds having the structure ##STR10## wherein R.sub.1 represents aryl;
- R.sub.2 represents aryl, alkyl or alkoxy;
- R.sub.3 represents hydrogen or lower alkyl;
- R.sub.4 represents hydrogen or hydroxyl; and
- R.sub.5 represents hydrogen or lower alkyl; and pharmaceutically acceptable salts of said compounds.
- 2. The compound of claim 1 which is 5-benzamido-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 3. The compound of claim 1 which is methyl 5-benzamido-4-oxo-6-phenylhexanoyl-L-prolinate, or its pharmaceutically acceptable salts.
- 4. The compound which is 5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl-L-proline, or its parmaceutically acceptable salts.
- 5. The compound which is 5-(4-pyridyl)carbonylamino-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 6. The compound which is 5-(2-furoylamino)-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 7. The compound which is 5-(2-tetrahydrofuroylamino)-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 8. The compound which is 5-o-toluoylamino-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 9. The compound which is 5-benzamido-4-oxo-6-(3,4-dimethoxyphenyl)hexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 10. The compound which is 5-benzamido-4-oxo-6-p-benzyloxyphenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 11. The compound which is 5-benzamido-4-oxo-6-p-hydroxyphenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 12. The compound which is 5-benzamido-4-oxo-6-(3-pyridyl)hexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 13. The compound of claim 1 which is 5-benzamido-4-oxo-6-pphenylhexanoyl-L-hydroxyproline, or its pharmaceutically acceptable salts.
- 14. The compound of claim 1 which is 5-benzamido-4-oxo-2-methyl-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 15. The compound of claim 1 which is 5-benzamido-4-oxo-2-isopropyl-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 16. The compound of claim 1 which is 5-n-butyloxycarbonylamino-4-oxo-6-phenylhexanoyl-L-proline, together with its pharmaceutically acceptable salts.
- 17. The compound of claim 1 which is methyl 5-n-butyloxycarbonylamino-4-oxo-2-methyl-6-phenylhexanoyl-L-prolinate, or its pharmaceutically acceptable salts.
- 18. The compond of claim 1 which is 5n-butyloxycarbonylamino-4-oxo-2-methyl-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 19. The compound of claim 1 which is 5-acetylamino-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 20. The compound of claim 1 which is 5-n-hexanoylamino-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 21. The compound of claim 1 which is 5-n-octanoylamino-4-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
- 22. The compound of claim 1 which is 5-n-decanoylamino-4-oxo-6-phenylhexanoyl-L-proline, or its pharmaceutically acceptable salts.
Parent Case Info
This application is a continuation-in-part of copending application, Ser. No. 44,685 filed June 1, 1979, now abandoned.
ORIGIN OF INVENTION
The invention described herein was in part made in the course of work under a grant from the National Institutes of Health, Department of Health and Human Services.
US Referenced Citations (10)
Non-Patent Literature Citations (3)
Entry |
Ondetti et al., Science, vol. 196, p. 441, (1977). |
Cushman et al., Biochemistry, vol. 16, p. 5484, (1977). |
Atkinson et al., Lancet, p. 557, (1979). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
44685 |
Jun 1979 |
|